AMENDMENT TO
RULES COMMITTEE PRINT 118–10
OFFERED BY MR. CRENSHAW OF TEXAS

Beginning on page 368, line 1, strike section 744 and insert the following:

SEC. 744. GRANT PROGRAM OF THE DEPARTMENT OF DEFENSE TO STUDY TREATMENT OF CERTAIN CONDITIONS USING CERTAIN PSYCHEDELIC SUBSTANCES.

(a) Establishment.—Not later than 90 days after the date of enactment of this Act, the Secretary of Defense shall award grants to eligible entities to conduct research on the treatment of members of the Armed Forces serving on active duty with a covered condition using covered psychedelic substances. Not later than 60 days after the date of the enactment of this Act, the Secretary shall designate a lead administrator to carry out the grant program under this section.

(b) Eligible Entities.—The Secretary may award a grant under this section to any of the following:

(1) A department or agency of the Federal Government or a State government.

(2) An academic institution.
(3) A nonprofit entity.

(4) A public or private entity.

(c) Use of Grant Funds.—A recipient of a grant awarded under this section may use the grant to—

(1) conduct one or more phase two clinical trials for the treatment of covered conditions that—

(A) include members of the Armed Forces serving on active duty as participants in the clinical trial; and

(B) use individual or group therapy assisted by covered psychedelic substances; or

(2) train practitioners to provide treatment to members of the Armed Forces serving on active duty for covered conditions using covered psychedelic substances.

(d) Participation in Clinical Trials.—The Secretary shall authorize any member of the Armed Forces serving on active duty who is diagnosed with a covered condition to participate in a clinical trial that is conducted using a grant awarded under this section or funds provided under subsection (e) and is authorized pursuant to section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), without regard to—
(1) whether the clinical trial involves a substance included in the schedule under section 202 of the Controlled Substances Act (21 U.S.C. 812); or

(2) section 912a of title 10, United States Code (article 112a of the Uniform Code of Military Justice).

(e) ADDITIONAL AUTHORITY.—Subject to the availability of appropriations, in addition to awarding grants under this section, the Secretary shall provide funds for a clinical research trial using covered psychedelic substances that is authorized pursuant to section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and includes members of the Armed Forces serving on active duty as participants in the trial.

(f) REPORT REQUIRED.—Not later than 180 days after the date of the enactment of this Act, and every 180 days thereafter, the Secretary shall submit to the Committees on Armed Services of the House of Representatives and the Senate a report on grants awarded under this section, including the following:

(1) Identification of clinics designated to host activities under such a grant.

(2) A description of entities to whom the Secretary has awarded such a grant.
(3) The number of members of the Armed Forces serving on active duty who participated in a clinical trial described in subsection (d).

(4) Information on the findings of such clinical trials.

(g) AUTHORIZATION OF APPROPRIATIONS.—

(1) INCREASE.—Notwithstanding the amounts set forth in the funding tables in division D, the amount authorized to be appropriated in section 1405 for the Defense Health Program, as specified in the corresponding funding table in section 4501 for “Defense Health Program, R&D research” is hereby increased by $15,000,000 (with the amount of such increase to be used in support of the grant program under this section).

(2) OFFSET.—Notwithstanding the amounts set forth in the funding tables in division D, the amount authorized to be appropriated in section 301, as specified in the corresponding funding table in section 4301, for “administration and service-wide activities, Office of the Secretary of Defense”, line 490, is hereby reduced by $15,000,000.

(h) DEFINITIONS.—In this section:

(1) The term “covered condition” means any of the following:
(A) Post-traumatic stress.

(B) Traumatic brain injury.

(2) The term “covered psychedelic substances” means any of the following:

(A) 3,4-Methylenedioxy-methamphetamine (commonly known as “MDMA”).

(B) Psilocybin.

(C) Ibogaine.

(D) 5-Methoxy-N,N-dimethyltryptamine (commonly known as “5-MeO-DMT”).

(3) The term “Secretary” means the Secretary of Defense.

(4) The term “State” has the meaning given such term in section 901 of title 32, United States Code.